Equasens: Stifel raises TP after sales

(CercleFinance.com) - While adjusting its target price from E85 to E86, Stifel maintains its "hold" rating on Equasens shares, prefering its peers Nexus and CompuGroup (both recommended as "buy", in the healthcare IT sector).


"Equasens delivered a solid Q1 top-line result, with organic growth reaching 14.0% (+11.1% excluding the Segur digitalisation plan in France)," he said after the trading update.

The broker raised its organic growth assumption for 2023 from 6.1% to 6.4%, but "we remain cautious given that the business can be lumpy, and the comparison bases will increasingly get tougher this year".


Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.